New Heart Valve Device Trial Begins

The TRIUMPH study is evaluating a new, less invasive way for adults to treat tricuspid regurgitation.

Updated on Oct. 31, 2026 in Heart Disease

Live Poll

Do you support the use of experimental devices in clinical trials to advance heart surgery?

The first three patients have been treated in the TRIUMPH clinical trial, a pivotal study testing a new transcatheter tricuspid valve replacement device. The study aims to evaluate the safety and efficacy of the device for patients with tricuspid regurgitation.

Why it matters

Tricuspid regurgitation can be a challenging condition to manage, and new transcatheter options are being investigated to provide less invasive alternatives for patients. This trial aims to determine how this specific device compares to existing, commercially available options.

The TRIUMPH study is a prospective, multicenter pivotal investigation device exemption study that has enrolled its first three patients. These participants are being randomized at a 2:1 ratio against a commercially available device, though long-term safety and efficacy remain unknown.

The players

Laplace Interventional

A medical device company focused on developing transcatheter technologies for the treatment of heart valve diseases.

Ballad Health

A regional healthcare provider that includes sites where the clinical trial procedures were performed.

Oklahoma Heart Institute

A specialized cardiac care center that participated in the initial treatment phase of the clinical trial.

The details

The Laplace Interventional device is designed to treat tricuspid regurgitation by replacing the valve without traditional open-heart surgery. Structural heart teams perform the procedure using either transjugular or transfemoral access to reach the heart. This approach allows for the placement of the replacement valve through the vascular system, minimizing the invasiveness of the procedure.

October 2026: The first three patients were treated in the clinical trial.

Health Landscape

The study marks a shift toward evaluating minimally invasive transcatheter solutions for complex heart valve conditions. It sits within a growing body of research aiming to expand treatment options beyond traditional open-heart surgery for patients with tricuspid valve issues.

For patients with tricuspid regurgitation, this trial represents a new avenue for potential future treatment options that may avoid traditional surgery. If you are managing this condition, it is worth discussing with your cardiologist whether upcoming clinical trials are appropriate for your specific case.

The takeaway

The TRIUMPH trial is actively evaluating a new, less invasive method for replacing the tricuspid valve. Patients interested in emerging treatment options for valvular heart disease should speak with their physician about current clinical research and whether they might be eligible for future trials.